Safety Surveillance of Traditional Chinese Medicine: Current and Future
- 443 Downloads
Herbal medicine, including traditional Chinese medicine, has been used for the prevention, treatment, and cure of disorders or diseases for centuries. In addition to being used directly as therapeutic agents, medicinal plants are also important sources for pharmacological drug research and development. With the increasing consumption of herbal products intended to promote better health, it is extremely important to assure the safety and quality of herbal preparations. However, under current regulation surveillance, herbal preparations may not meet expectations in safety, quality, and efficacy. The challenge is how to assure the safety and quality of herbal products for consumers. It is the responsibility of producers to minimize hazardous contamination and additives during cultivation, harvesting, handling, processing, storage, and distribution. This article reviews the current safety obstacles that have been involved in traditional Chinese herbal medicine preparations with examples of popular herbs. Approaches to improve the safety of traditional Chinese medicine are proposed.
KeywordsTraditional Chinese Medicine Herbal Product Aristolochic Acid Botanical Drug Traditional Chinese Medicine Formula
The authors thank Christopher C. Chen for scientific editorial assistance with this article. This work was supported by the National Cancer Institute (Grant No. 1PO1CA154295-01A1). Yung-Chi Cheng is a fellow of the National Foundation for Cancer Research, USA.
The views expressed in this article are personal and do not reflect the official position or policies of the authors’ respective organizations.
Conflict of interest
Yung-Chi Cheng, Shwu-Huey Liu, and Zaoli Jiang are the co-inventors of PHY906 patents. Wu-Chang Chuang and Wing Lam have no conflicts of interest that are directly relevant to the content of this article.
- 1.Barnes PM, Bloom B, Nahin R. CDC National Health Statistics Report #12. Complementary and alternative medicine use among adults and children: United States, 2007. 10 Dec 2008.Google Scholar
- 2.Nahin R, Barnes PM, Stussman BJ, et al. CDC National Health Statistics Report #18. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. 30 July 2009.Google Scholar
- 4.Friesen D. Traditional Chinese Medicine: Business blockbuster or false fad? CKGSB Knowledge. http://knowledge.ckgsb.edu.cn/2013/01/08/china/traditional-chinese-medicine-business-blockbuster-or-false-fad/. 8 Jan 2013.
- 5.Luo Xiwen tr. Bencao Gangmu: compendium of materia medica. vol 6. Foreign Languages Press; 2003.Google Scholar
- 6.Maoshiny N. The yellow Emperor’s Classic of Medicine: a new translation of the Neijing suwen with commentary. Shambhala Publications, Inc.; 1995.Google Scholar
- 7.Division of Health Statistics. Statistical Annual Report of Medical Care, National Health Insurance. Taipei: The ROC Department of Health; 2009.Google Scholar
- 8.U.S. Food and Drug Administration Web site. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108379.htm.
- 12.Hughes D. New EU regulations on herbal medicines come into force. BBC News. 2011.Google Scholar
- 14.Dietary supplements. U.S. Food and Drug Administration Web site. Accessed at www.fda.gov/Food/DietarySupplements.
- 16.FDA. Guidance for Industry. Botanical Drug Products (FDA, DC, June 2004). http://www.fda.gov/cder/guidance/4592fnl.pdf.
- 18.Veregen: a botanical for treatment of genital warts. Obstet Gynecol. 2008;112(3):691–2.Google Scholar
- 22.Nyirimigabo E, Xu Y, Li Y, et al. A review on phytochemistry, pharmacology and toxicology studies of Aconitum. J Pharm Pharmacol. 2014 [Epub ahead of print].Google Scholar
- 33.Hsu HY, Hsu CS. Commonly used Chinese herb formulas with illustrations. Los Angeles: Oriental Healing Art Institute; 1980.Google Scholar
- 34.Pharmacopoeia of the People’s Republic of China. vol 1, 1997.Google Scholar
- 35.Fu PP, Yang YC, Xia Q, et al. Pyrrolizidine alkaloids-tumorigenic components in Chinese herbal medicines and dietary supplements. J Food Drug Anal. 2002;10(4):198–211.Google Scholar
- 37.Blum D. The trouble with rice. N Y Times. 2014. http://nyti.ms/1eIX0T4
- 41.Genuis SJ, Schwalfenberg G, Siy A-KJ, Rodushkin I. Toxic element contamination of natural health products and pharmaceutical preparations. Sem DS, editor. PLoS One. 2012;7(11):e49676.Google Scholar
- 45.Chen LL, Zhou X, Zhang YX, et al. Chemical composition and Heavy metal content of radix of Panax notoginseng from different sources. In: Proceedings of the 13th Meeting of Consortium for Globalization of Chinese Medicine. 2014.Google Scholar
- 48.Greenpeace. Chinese Herbs: elixir of health or pesticide cocktail [report on the internet]. Available from: http://www.greenpeace.org/eastasia/campaigns/food-agriculture/Chinese-Herbs-Elixir-of-Health/.
- 49.Michael W. Mystery malady kills more bees, heightening worry on farms. N Y Times. 2013. http://www.nytimes.com/2013/03/29/science/earth/soaring-bee-deaths-in-2012-sound-alarm-on-malady.html
- 51.Kan WL, Ma B, Lin G. Sulfur fumigation processing of traditional Chinese medicinal herbs: beneficial or detrimental? Front Pharmacol. 2011;27(2):84.Google Scholar
- 54.Rao WW, Jiang L, Zhao CY, et al. Identification of chemical industry dyes in adulteration of Chinese medicinal materials. J Pharm Anal. 2007;27(11):1742–5.Google Scholar
- 55.Liu SH, Cheng YC, Saif MW. Controlling chemotherapy-related side effects with Chinese medicine. Chapter 7 of “Supportive Cancer Care with Chinese Medicine”. Springer Science; (2010).Google Scholar
- 67.FAO (Food and Agriculture Organization of United Nations). Manual on the Application of the HACCP System in Mycotoxin Prevention and Control, 73, FAO Food and Nutrition Paper, Rome. 2001.Google Scholar
- 76.Gurley BJ, Swain A, Williams DK, et al. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: Comparative effects of St. John’s wort, echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res. 2008;52(7):772–9.CrossRefPubMedCentralPubMedGoogle Scholar
- 79.Yan M, Chen JL, Xu LW, et al. Navigating traditional Chinese medicine network pharmacology and computational tools. Evid Based Complement Alternat Med. 2013;2013:731969.Google Scholar
- 82.Zhang W, Saif MW, Dutschman GE, et al. Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). J Chromatogr A. 2010;1217(37):5785–93.CrossRefPubMedCentralPubMedGoogle Scholar
- 84.Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine: how to practice and teach EBM. Edinburgh: Churchill Livingstone; 2000.Google Scholar
- 87.Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina (CAESA) ClinicalTrials.gov Identifier: NCT01659580.Google Scholar
- 88.Lam W, Bussom S, Guan F, et al. PHY906, a four-herb Chinese medicine formula first described 1,800 years ago, reduces irinotecan-induced intestinal damage through anti-inflammatory effects and by promotion of the repopulation of intestinal progenitor cells. Sci Transl Med. 2010;2(45):45ra59.CrossRefPubMedGoogle Scholar